TipRanks

Notifications

Translate Bio (TBIO) Gets a Buy Rating from William Blair

William Blair analyst Myles Minter reiterated a Buy rating on Translate Bio (TBIOResearch Report) yesterday. The company’s shares closed last Friday at $18.36.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Translate Bio has an analyst consensus of Moderate Buy, with a price target consensus of $22.67.

See today’s analyst top recommended stocks >>

Translate Bio’s market cap is currently $1.41B and has a P/E ratio of -68.10. The company has a Price to Book ratio of 5.29.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.